Sacubitril
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Sacubitril: From Heart Failure to Diabetic Nephropathy
One-Sentence Summary
Sacubitril is the neprilysin-inhibitor component of the Sacubitril/Valsartan (ARNI) combination, whose approved use is heart failure with reduced ejection fraction. Among 10 TxGNN-predicted indications for this candidate, only Diabetic Nephropathy is backed by real clinical and mechanistic evidence — 2 clinical trials and 17 publications — while the model’s top-ranked hit is flagged in the evidence pack itself as a likely false-positive match. Sacubitril (DB09292) as a single entity is currently not registered with SAHPRA and has no South African market presence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established in South African registration data (0 SAHPRA licenses); per the evidence pack, Sacubitril is a component of Sacubitril/Valsartan (Entresto), approved elsewhere for heart failure with reduced ejection fraction |
| Predicted New Indication | Diabetic Nephropathy |
| TxGNN Prediction Score | 99.50% |
| Evidence Level | L3 |
| South Africa Market Status | Not marketed (未上市) |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Sacubitril is flagged as a data gap at the drug level. However, the evidence pack’s own literature-derived rationale indicates that Sacubitril (activated to LBQ657) inhibits neprilysin, reducing degradation of natriuretic peptides (ANP/BNP/CNP). This enhances natriuretic-peptide signalling, promoting natriuresis, lowering intraglomerular pressure, and counteracting excessive RAAS activation and renal fibrosis — mechanisms with direct relevance to diabetic kidney disease pathophysiology.
Heart failure and diabetic nephropathy frequently co-exist and share overlapping haemodynamic and neurohormonal pathways (RAAS overactivation, sodium retention, glomerular hyperfiltration). The approved use of Sacubitril/Valsartan in heart failure — a condition with well-documented renal cross-talk — provides a plausible mechanistic bridge to a renoprotective effect in diabetic nephropathy, consistent with the multiple preclinical and clinical observations in the evidence pack.
Note on TxGNN ranking: the single highest-scoring prediction (brain small vessel disease with ocular anomalies, score 99.58%) was reviewed and found to have no supporting literature — the 19 retrieved publications are unrelated case/review reports on congenital ophthalmic and genetic syndromes, none mentioning Sacubitril or neprilysin. The evidence pack classifies this as a TxGNN embedding similarity artefact (“noise match”) and assigns it Evidence Level L5 / Hold. The same applies to 7 other ranked candidates (autosomal dominant familial hematuria syndrome, rheumatoid arthritis, hemoglobinopathy, sclerosing cholangitis, colobomatous microphthalmia-rhizomelic dysplasia syndrome, homozygous familial hypercholesterolemia, chromosome 16p deletion, beta-thalassemia), all L5/Hold with zero supporting trials or literature. Diabetic Nephropathy (rank 3, score 99.50%) is therefore the only candidate in this pack with a credible evidence base and is used as the basis for this report.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04735354 | N/A | Completed | 268 | Non-interventional, retrospective real-world EMR analysis of Sacubitril/Valsartan prescribing patterns in Indian HFrEF patients over 1.5 years; not designed around diabetic nephropathy as a primary endpoint, so provides only indirect renal-outcome signal |
| NCT06501651 | Phase 4 | Not yet recruiting | 297 | Prospective, randomized, controlled multicentre study comparing Sacubitril/Valsartan vs Valsartan in patients with mild-to-moderate essential hypertension and Type 2 diabetic nephropathy, 12-week treatment, 2:1 randomization; no data generated yet |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29661699 | 2018 | Secondary analysis of RCT (PARADIGM-HF) | Lancet Diabetes Endocrinol | Neprilysin inhibition assessed for renal function effects in Type 2 diabetic patients with chronic HF on target-dose RAAS inhibitors; the strongest clinical-trial-derived evidence in this pack |
| 37549515 | 2023 | Clinical/comparative cohort | Int Immunopharmacol | Sacubitril/Valsartan + nifedipine combination improved renal function outcomes vs valsartan + nifedipine in 112 diabetic nephropathy patients with hypertension |
| 40416927 | 2025 | Clinical cohort (BOLD-MRI) | Diabetes Metab Syndr Obes | Imaging-based (BOLD-MRI) evaluation of renal protective effects of Sacubitril/Valsartan in Type 2 diabetic patients |
| 37625003 | 2023 | Review | Diabetes Care | Update on therapeutic pillars slowing diabetic kidney disease progression, situates neprilysin inhibition among newer mechanism-based options |
| 34441977 | 2021 | Review | J Clin Med | Reviews diabetes-heart failure pathophysiology, including diabetic nephropathy as a shared comorbidity pathway |
| 35165832 | 2022 | Review | Curr Hypertens Rep | Reviews newer antihypertensive drug classes, including ARNI, for mitigating hypertensive target-organ (renal) damage |
| 34734359 | 2023 | Review | Heart Fail Rev | Reviews disease-modifying drugs, including Sacubitril/Valsartan, in diabetic HFrEF patients |
| 34431635 | 2021 | Review | Rev Med Suisse | Reviews the potential role of Sacubitril/Valsartan in Type 2 diabetes, including renal effects |
| 35992034 | 2022 | Preclinical (rat) | Diabetes Metab Syndr Obes | Sacubitril/Valsartan slowed early diabetic nephropathy progression via NLRP3 inflammasome pathway inhibition |
| 32596035 | 2020 | Preclinical (rat) | PeerJ | LCZ696 (Sacubitril/Valsartan) reduced oxidative stress, NF-κB-mediated inflammation and glomerulosclerosis in diabetic rats |
South Africa Market Information
Sacubitril (DB09292) currently has no SAHPRA registrations and is not marketed in South Africa as a single entity. No product listings, dosage forms, or approved indication text are available in the evidence pack for this drug in the South African market.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA. Key warnings, contraindications, and drug-drug interaction data for Sacubitril are marked as an unresolved (Blocking-severity) data gap in this evidence pack, meaning a preliminary safety assessment cannot yet be completed.
Conclusion and Next Steps
Decision: Hold
Rationale:
- Sacubitril has no SAHPRA registration and no South African market presence, and the underlying Professional Information/safety data needed for even a preliminary safety review is an unresolved Blocking-severity gap.
- The only credible predicted indication (Diabetic Nephropathy) has supportive but not yet definitive evidence — no completed trial with diabetic nephropathy as a primary endpoint; the sole purpose-designed Phase 4 RCT (NCT06501651) has not yet started recruiting.
To proceed, the following is needed:
- SAHPRA-approved PI covering warnings, contraindications, and drug interactions (currently Blocking data gap, DG001)
- Confirmation of whether Sacubitril/Valsartan (Entresto) as a combination product holds separate SAHPRA registration in South Africa
- Full mechanism-of-action documentation for Sacubitril (currently High-severity data gap, DG002)
- Results from NCT06501651 once recruitment and follow-up are complete
- No further action needed on the 8 other TxGNN-ranked candidates in this pack (including the top-scoring “brain small vessel disease” prediction) — all lack any supporting trial or literature evidence and are assessed as low-confidence model artefacts
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.